Literature DB >> 34193118

Menopausal symptoms are associated with oral sensory complaints in perimenopausal women: an observational study.

Tomoharu Taga1,2, Kayoko Ito3, Kiyoshi Takamatsu4, Mariko Ogawa4, Saori Funayama5, Makoto Inoue1,5.   

Abstract

BACKGROUND: Perimenopausal women experience a wide variety of systemic symptoms: hot flashes, sweating, mental health concerns and various oral sensory complaints (OSC). OSC in perimenopausal women include xerostomia, taste disturbance and burning mouth. However, the factors associated with these OSC have not been identified. The purpose of this investigation was to elucidate the factors associated with OSC in perimenopausal women.
METHODS: The study cohort comprised 43 perimenopausal women aged 45-55 years. Data on medical history, medications, menstrual status, menopausal symptoms, quality of life, xerostomia, taste disturbance and burning mouth were collected. Volumes of unstimulated and stimulated saliva were measured. Tongue coating was evaluated according to a tongue coating index. Univariate analysis was performed to identify factors significantly associated with having xerostomia, taste disturbance, burning mouth and more than two OSC (2OSC). Next, the factors strongly associated with these symptoms were examined by logistic regression analysis.
RESULTS: The number of menopausal symptoms was significantly higher, and volume of unstimulated saliva was significantly lower in participants with xerostomia, taste disturbance, burning mouth or 2OSC than in those without these characteristics. Agents targeting the central nervous system were more frequently taken by participants with burning mouth and 2OSC than by those without these characteristics. According to logistic regression analysis, the number of menopausal symptoms was an explanatory variable for xerostomia, taste disturbance, burning mouth and 2OSC.
CONCLUSIONS: Our findings suggested that OSC associated with the number of menopausal symptoms. Management of menopausal symptoms may decrease OSC, leading to improved quality of life of perimenopausal women.

Entities:  

Keywords:  Burning mouth; Menopause; Oral sensory complaint; Taste disturbance; Xerostomia

Mesh:

Year:  2021        PMID: 34193118      PMCID: PMC8243452          DOI: 10.1186/s12905-021-01401-6

Source DB:  PubMed          Journal:  BMC Womens Health        ISSN: 1472-6874            Impact factor:   2.809


Background

During perimenopausal period, many women experience a wide variety of systemic symptoms, including symptoms such as hot flashes, sweating, mental health concerns, and mucocutaneous symptoms, all of which can markedly decrease their quality of life (QOL). These symptoms are mainly attributable to a decline in production of female sex hormones. Various oral sensory disturbances, including xerostomia, taste disturbance and burning mouth have also been reported [1]. These sensory disturbances have been classified as oral sensory complaints (OSC) [2, 3]. Xerostomia is defined as a subjective experience of a dry mouth [4], whereas hyposalivation is an objective reduction in salivary secretion [5]. Causes of xerostomia vary widely, including Sjögren syndrome, psychological stress, radiation therapy, medications and salivary gland tumors. An association between xerostomia and menopausal status has been widely reported [1, 6]. Burning mouth syndrome is defined by the International Association for the Study of Pain as a burning pain in the tongue and/or other oral mucous membranes in the absence of clinical signs and abnormal laboratory findings [7]. Burning mouth syndrome occurs in 10–40% of women of perimenopausal age, decreasing their QOL [8]. Indeed, in one study 79.5% of physicians and gynecologists reported encountering the complaints xerostomia, taste disturbance, burning mouth or temporomandibular disorders [9]. After ascertaining the presence of these symptoms, 58.5% of these physicians reported referring affected women to specialized clinics. In other words, the remaining women potentially failed to receive appropriate medical care. If specific menopausal symptoms, or the number of such symptoms, are associated with OSC in perimenopausal women, treatment of those symptoms would likely contribute to improving their QOL. However, to our knowledge, no reported studies have investigated the factors associated with OSC in individual perimenopausal women. The purpose of this study was to identify those factors.

Subjects and methods

Participants

Before the study was initiated, a required sample size of 43 was calculated using software (G*power 3.1.9.7) and an effect size of 0.5, α-value of 0.05, and power of 0.9. Inclusion criteria were: women aged 45 to 55 years. Exclusion criteria were: pregnant women or women who had undergone previous hysterectomy or bilateral oophorectomy. The participants were drawn from patients and staff of the departments of Oral Surgery in Fukui Prefectural Hospital and Oral Rehabilitation in Niigata Medical and Dental Hospital in Japan between 2018 and 2020.

Questionnaires

Characteristics of participants and oral symptoms

Each study participant filled out questionnaires that included items on age, medical history, medications, menstrual status, menopausal symptoms, history of treatment for menopausal symptoms, oral symptoms including xerostomia, taste disturbance and burning mouth (Additional file 1: Supplementary table 1). Reported medication history was confirmed by checking the individual’s medical records. Package inserts were examined to determine whether the reported medications had the adverse effects of xerostomia, taste disturbance or burning mouth.

Menopausal symptoms

To assess menopausal symptoms, we used the menopausal symptom checklist for Japanese women [10], which includes 21 items (Additional file 2: Supplementary table 2). These items are allotted scores on a three-point scale (2: severe, 1: mild, 0: none). This checklist was developed for Japanese women [10] whereas the Kuppermann index was developed for American women [11]. We evaluated xerostomia, taste disturbance and burning mouth using the same three-point scale.

QOL

The Japanese version of the 36-Item Short-Form Health (SF-36) [12] was used to assess QOL. SF-36 includes one multi-item scale that assesses eight health concepts: (1) limitations in physical activities because of health problems; (2) limitations in social activities because of physical or emotional problems; (3) limitations in usual role activities because of physical health problems; (4) bodily pain; (5) general mental health (psychological distress and well-being); (6) limitations in usual role activities because of emotional problems; (7) vitality (energy and fatigue); and (8) general health perceptions [12].

Volume of saliva and tongue coating

All participants were asked not to drink or eat for at least 1 h before assessment. We measured the volume of unstimulated saliva using the 10-min spitting method; 1 g of saliva was converted to 1 mL [13]. Stimulated saliva volume was measured by the Saxon method [14]. Tongue coating was evaluated with the Tongue Coating Index (TCI) [15], which entails evaluating the thickness of tongue coating in nine sections of the tongue surface (Score 0: no tongue coating visible; Score 1: tongue coating thin, papillae of tongue visible; Score 2: tongue coating thick, papillae of tongue not visible). The TCI is obtained by dividing the total score by 18 and then multiplying by 100.

Statistical analysis

Participants with self-reported mild-to-severe xerostomia, taste disturbance or burning mouth were considered to have the relevant symptom. Participants with two or more of these symptoms were classified as having two or more OSC (2OSC). The presence of mild-to-severe menopausal symptoms was determined on the basis of self-reporting. We used a three-component summary score (physical, mental, and role/social component summaries) to classify responses to the SF-36 questionnaire. We performed univariate analysis to investigate the relationship between xerostomia, taste disturbance, burning mouth, and 2OSC and the other evaluated characteristics. The Mann–Whitney U test was performed for numerical data because all data were non-normally distributed. χ2 test was performed for categorical data. Logistic regression analysis using a stepwise method was employed to assess factors associated with xerostomia, taste disturbance, burning mouth, and 2OSC. The presence of xerostomia was treated as an objective variable, whereas variables showing significant associations by the χ2 and Mann–Whitney U tests were treated as explanatory variables. In choosing explanatory variables, we considered the correlations with each factor and selected only one of the items with a Spearman’s correlation coefficient of 0.7 or more. The statistical software used was SPSS 26.0 (IBM, Japan). Statistical significance was set at P < 0.05.

Results

Forty-three 45–55-year-old women participated in this survey and all of them completed the questionnaires and measurement of volume of saliva and tongue coatings.

Oral sensory complains and characteristics

Characteristics of the participants are shown in the left-hand column of Table 1. Of the 43 participants, 22 (51.2%) had xerostomia, 12 (27.9%) had taste disturbance, 13 (30.2%) had burning mouth and 15 (34.9%) had 2OSC. The results of univariate analysis are shown in Table 1. Women with taste disturbance and 2OSC reported taking significantly more medications than did the other participants (p = 0.04 and p < 0.001, respectively). Agents targeting the central nervous system were more frequently taken by participants with burning mouth and 2OSC than by those without these characteristics (p = 0.014 and p = 0.003, respectively).
Table 1

Factors associated with having xerostomia, taste disturbance, burning mouth and two or more oral sensory complaints (univariate analysis)

TotalXerostomiaTaste disturbanceBurning mouth2OSC
(n = 43)no (n = 21)yes (n = 22)p valueno (n = 31)yes (n = 12)p valueno (n = 30)yes (n = 13)p valueno (n = 28)yes (n = 15)p value
Characteristics
Agemean ± SD48.7 ± 4.749.2 ± 348.3 ± 5.80.9248.9 ± 5.248.3 ± 2.90.2548.5 ± 5.149.2 ± 3.40.8948.5 ± 5.449.3 ± 2.80.86
BMImean ± SD22.3 ± 3.722.6 ± 3.621.9 ± 3.90.3421.9 ± 3.923.2 ± 3.40.1721.6 ± 3.223.8 ± 4.50.0821.6 ± 3.423.5 ± 4.20.13
Marriedn (%)31 (72.1)17 (81.0)14 (63.6)0.2123 (74.2)8 (66.7)0.4523 (76.7)8 (61.5)0.2622 (78.6)9 (60.0)0.17
Childrenn (%)12 (27.9)4 (19.0)8 (36.4)0.218 (25.8)4 (33.3)0.456 (20.0)6 (46.2)0.096 (21.4)6 (40.0)0.17
Jobn (%)36 (83.7)19 (90.5)17 (77.3)0.2325 (80.6)11 (91.7)0.3625 (83.3)11 (84.6)0.6524 (85.7)12 (80.0)0.47
Smokingn (%)1 (2.3)0 (0.0)1 (4.5)0.511 (3.2)0 (0.0)0.720 (0.0)1 (7.7)0.300 (0.0)1 (6.7)0.35
Medical history
Hypertensionn (%)5 (11.6)3 (14.3)2 (9.1)0.484 (12.9)1 (8.3)0.573 (10.0)2 (15.4)0.483 (10.7)2 (13.3)0.58
Psychosisn (%)5 (11.6)1 (4.8)4 (18.2)0.193 (9.7)2 (16.7)0.431 (3.3)4 (30.8)0.021 (3.6)4 (26.7)0.04
Medication
Number of drugsmean ± SD2.2 ± 4.40.7 ± 1.13.6 ± 5.70.071.5 ± 3.23.9 ± 6.30.041.3 ± 3.14.1 ± 6.20.040.8 ± 1.84.7 ± 6.4 < 0.001
CNS agentn (%)7 (16.3)2 (9.5)5 (23.8)0.213 (10.0)4 (33.3)0.092 (6.7)5 (41.7)0.011 (3.6)6 (42.9)0.00
Antihypertensiven (%)3 (7.0)1 (4.8)2 (9.5)0.502 (6.7)1 (8.3)0.651 (3.3)2 (16.7)0.191 (3.6)2 (14.3)0.25
Adverse effect of medication
Xerostomian (%)15 (34.9)7 (33.3)8 (38.1)0.758 (26.7)7 (58.3)0.068 (26.7)7 (58.3)0.066 (21.4)9 (64.3)0.01
Taste disturbancen (%)10 (23.3)5 (23.8)5 (23.8)1.008 (26.7)2 (16.7)0.47 (23.3)3 (25.0)0.606 (21.4)4 (28.6)0.44
Burning mouthn (%)1 (2.3)0 (0.0)1 (4.8)0.310 (0.0)1 (8.3)0.291 (3.3)0 (0.0)0.710 (0.0)1 (7.1)0.33
Sleep
Sleeping duration (min)mean ± SD356.7 ± 82.7346.2 ± 55.5366.8 ± 102.60.39349.4 ± 88.5375.8 ± 64.90.17348 ± 85.8376.9 ± 74.30.08349.3 ± 84.1370.7 ± 80.90.11
Lach of sleeping timen (%)18 (41.9)8 (38.1)10 (45.5)0.6213 (41.9)5 (41.7)0.9914 (46.7)4 (30.8)0.3312 (42.9)6 (40.0)0.86
Quarity of sleepingn (%)19 (44.2)8 (38.1)11 (50.0)0.4313 (41.9)6 (50.0)0.6313 (43.3)6 (46.2)0.8612 (42.9)7 (46.7)0.81
Quarity of life
SDS totalmean ± SD42.3 ± 9.738.9 ± 8.645.6 ± 9.70.0541.4 ± 9.544.7 ± 10.30.2441.5 ± 1044.2 ± 9.10.4540.9 ± 9.745.1 ± 9.40.21
PCSmean ± SD47.6 ± 10.349.4 ± 8.245.9 ± 11.90.2248.4 ± 9.445.5 ± 12.50.4647.5 ± 9.547.7 ± 12.30.8349.2 ± 7.344.6 ± 14.20.33
MCSmean ± SD45.0 ± 9.749.4 ± 7.640.8 ± 9.8 < 0.00146.9 ± 8.840 ± 10.70.0547.2 ± 939.7 ± 9.70.0347.9 ± 8.339.4 ± 10.10.01
RCSmean ± SD50.6 ± 11.353.8 ± 7.247.6 ± 13.70.2351.9 ± 9.447.2 ± 15.10.4349.9 ± 1252.2 ± 9.60.6251.2 ± 1049.5 ± 13.70.96
Threaten of cancern (%)37 (86.0)18 (85.7)19 (86.4) < 0.00127 (87.1)10 (83.3)0.5525 (83.3)12 (92.3)0.4025 (89.3)12 (80.0)0.34
Menopause
Menopausen (%)17 (39.5)7 (33.3)10 (45.5)0.3115 (48.4)2 8(16.7)0.0611 (36.7)6 (46.2)0.4011 (39.3)6 (40.0)0.61
Treatment of menopausal symptomn (%)5 (11.6)1 (4.8)4 (18.2)0.192 (6.5)3 (25.0)0.124 (13.3)1 (7.7)0.522 (7.1)3 (20.0)0.22
Number of menopausal symptommean ± SD11.3 ± 5.08.6 ± 4.013.9 ± 4.4 < 0.00110.2 ± 4.314.2 ± 5.60.0210.3 ± 4.313.7 ± 5.70.049.3 ± 3.815.1 ± 4.8 < 0.001
Hot flashes of face or upper bodyn (%)23 (53.5)11 (52.4)12 (54.5)0.8915 (48.4)8 (66.7)0.2818 (60.0)5 (38.5)0.1914 (50.0)9 (60.0)0.53
Sweat easilyn (%)29 (67.4)14 (66.7)15 (68.2)0.9220 (64.5)9 (75.0)0.3920 (66.7)9 (69.2)0.5817 (60.7)12 (80.0)0.17
Unable to fall asleep at nightn (%)14 (32.6)7 (33.3)7 (31.8)0.928 (25.8)6 (50.0)0.138 (26.7)6 (46.2)0.186 (21.4)8 (53.3)0.04
Fall asleep but often awake at nightn (%)23 (53.5)8 (38.1)15 (68.2)0.0513 (41.9)10 (83.3)0.0113 (43.3)10 (76.9)0.0411 (39.3)12 (80.0)0.01
Easily excitable, often irritablen (%)29 (67.4)10 (47.6)19 (86.4)0.0119 (61.3)10 (83.3)0.1519 (63.3)10 (76.9)0.3117 (60.7)12 (80.0)0.17
Always anxiousn (%)22 (51.2)5 (23.8)17 (77.3) < 0.00113 (41.9)9 (75.0)0.0513 (43.3)9 (69.2)0.1210 (35.7)12 (80.0)0.01
Worry about minor thingsn (%)26 (60.5)8 (38.1)18 (81.8) < 0.00118 (58.1)8 (66.7)0.4416 (53.3)10 (76.9)0.1514 (50.0)12 (80.0)0.06
Worry and often become depressedn (%)23 (53.5)4 (19.0)19 (86.4) < 0.00114 (45.2)9 (75.0)0.0815 (50.0)8 (61.5)0.4911 (39.3)12 (80.0)0.01
Lack of energy, easily tiredn (%)25 (58.1)7 (33.3)18 (81.8) < 0.00116 (51.6)9 (75.0)0.1615 (50.0)10 (76.9)0.1012 (42.9)13 (86.7)0.01
Tired feeling of eyesn (%)38 (88.4)16 (76.2)22 (100.0)0.0227 (87.1)11 (91.7)0.5725 (83.3)13 (100.0)0.1523 (82.1)15 (100.0)0.10
Forgetfuln (%)29 (67.4)13 (61.9)16 (72.7)0.4521 (67.7)8 (66.7)0.6119 (63.3)10 (76.9)0.3118 (64.3)11 (73.3)0.40
Dizzinessn (%)17 (39.5)7 (33.3)10 (45.5)0.429 (29.0)8 (66.7)0.0311 (36.7)6 (46.2)0.568 (28.6)9 (60.0)0.04
Heart pounds quicklyn (%)15 (34.9)3 (14.3)12 (54.5)0.0110 (32.3)5 (41.7)0.418 (26.7)7 (53.8)0.096 (21.4)9 (60.0)0.01
Tight feeling of chestn (%)7 (16.3)2 (9.5)5 (22.7)0.233 (9.7)4 (33.3)0.083 (10.0)4 (30.8)0.114 (14.3)3 (20.0)0.47
Headachesn (%)25 (58.1)9 (42.9)16 (72.7)0.0516 (51.6)9 (75.0)0.1616 (53.3)9 (69.2)0.3313 (46.4)12 (80.0)0.03
Shoulder or neck stiffnessn (%)39 (90.7)20 (95.2)19 (86.4)0.3229 (93.5)10 (83.3)0.3127 (90.0)12 (92.3)0.6525 (89.3)14 (93.3)0.56
Back or low back painn (%)29 (67.4)13 (61.9)16 (72.7)0.4519 (61.3)10 (83.3)0.1519 (63.3)10 (76.9)0.3117 (60.7)12 (80.0)0.17
Joint of hands and feet painfuln (%)21 (48.8)9 (42.9)12 (54.5)0.4413 (41.9)8 (66.7)0.1513 (43.3)8 (61.5)0.2711 (39.3)10 (66.7)0.09
Coldnessn (%)28 (65.1)8 (38.1)20 (90.9) < 0.00119 (61.3)9 (75.0)0.3218 (60.0)10 (76.9)0.2414 (50.0)14 (93.3) < 0.001
Numbness of hands and feetn (%)14 (32.6)6 (28.6)8 (36.4)0.597 (22.6)7 (58.3)0.038 (26.7)6 (46.2)0.186 (21.4)8 (53.3)0.04
Recently sensitive to soundn (%)12 (27.9)1 (4.8)11 (50.0) < 0.0018 (25.8)4 (33.3)0.456 (20.0)6 (46.2)0.094 (14.3)8 (53.3)0.01
Oral symptom
Xerostomian (%)22 (51.2)14 (45.2)8 (66.7)0.2113 (43.3)9 (69.2)0.129 (32.1)13 (86.7) < 0.001
Taste disturbancen (%)12 (27.9)4 (19.0)8 (36.4)0.216 (20.0)6 (46.2)0.092 (7.1)10 (66.7) < 0.001
Burning mouthn (%)13 (30.2)4 (19.0)9 (40.9)0.087 (22.6)6 (50.0)0.092 (7.1)11 (73.3) < 0.001
Unstimulated saliva (mL/min)mean ± SD0.3 ± 0.20.4 ± 0.20.2 ± 0.2 < 0.0010.4 ± 0.20.2 ± 0.10.020.4 ± 0.20.2 ± 0.20.030.4 ± 0.20.2 ± 0.20.01
Stimulated saliva (g)mean ± SD3.4 ± 2.03.4 ± 1.53.4 ± 2.40.873.7 ± 2.22.9 ± 1.60.383.6 ± 2.13.1 ± 1.90.843.7 ± 2.23 ± 1.80.61
TCImean ± SD23.5 ± 14.823.8 ± 13.423.2 ± 16.30.9926.3 ± 14.116.2 ± 14.70.0426.3 ± 14.117.1 ± 150.0426.6 ± 12.817.8 ± 170.05

2OSC, two or more oral sensory complaints; CNS, central nervous system; MCS, mental component summary; PCS, physical component summary; RCS, role/social component summary; TCI, tongue coating index

Factors associated with having xerostomia, taste disturbance, burning mouth and two or more oral sensory complaints (univariate analysis) 2OSC, two or more oral sensory complaints; CNS, central nervous system; MCS, mental component summary; PCS, physical component summary; RCS, role/social component summary; TCI, tongue coating index

Oral sensory complains and QOL

Scores on the mental component summary of the QOL questionnaire were significantly lower in women with xerostomia (p < 0.001), burning mouth (p = 0.03) and 2OSC (p = 0.01) than in the other participants.

Oral sensory complains and menopausal symptoms

Women with xerostomia (p < 0.001), taste disturbance (p = 0.02) burning mouth (p = 0.04) and 2OSC (p < 0.001) had significantly more menopausal symptoms than did the other participants.

Oral sensory complains and saliva volume

Unstimulated saliva volume was significantly smaller in participants who had xerostomia (p < 0.001), taste disturbance (p = 0.02) burning mouth (p = 0.03) and 2OSC (p = 0.01) than in those who did not.

Factors associated with oral symptoms

As shown in Table 2, logistic regression analysis showed associations between the number of menopausal symptoms and xerostomia, taste disturbance, burning mouth and 2OSC. Number of menopausal symptom was to be an explanatory variable for xerostomia (odds ratio 1.331), taste disturbance (odds ratio 1.204), burning mouth (odds ratio 1.162) and 2OSC (odds ratio 1.358) with statistical significantly difference. The discriminant probability was 69.8% for xerostomia, 81.4% for taste disturbance, 78.6% for burning sensation and 85.7% for 2OSC (p < 0.001).
Table 2

Factors associated with xerostomia, taste disturbance, burning mouth and two or more oral sensory complaints (logistic regression analysis)

Objective variableExplanatory variableOdds ratio95% confidence intervalP
XerostomiaNumber of menopausal symptoms1.3311.112–1.5920.002
Taste disturbanceNumber of menopausal symptoms1.2041.026–1.4130.023
Burning mouthNumber of menopausal symptoms1.1621.002–1.3470.048
2OSCNumber of menopausal symptoms1.3581.121–1.6460.002

2OSC, two or more oral sensory complaints

Factors associated with xerostomia, taste disturbance, burning mouth and two or more oral sensory complaints (logistic regression analysis) 2OSC, two or more oral sensory complaints

Discussion

To the best of our knowledge, this is a first reported study to investigate the factors associated with xerostomia, taste disturbance, burning mouth and 2OSC in perimenopausal women simultaneously. Logistic regression analysis showed associations between the number of menopausal symptoms and xerostomia, taste disturbance, burning mouth and 2OSC. Moreover, unstimulated saliva volume was associated with these symptoms according to univariate analysis. The basic cause of menopausal symptoms is the complex relationship of estrogen metabolism and the autonomic nervous system [16]. Salivary secretion is regulated by the autonomic nervous system and unstimulated saliva volume was smaller in participants with menopausal symptoms in the present study. Sensations of coldness result from contraction of peripheral blood vessels, which may also be related to autonomic nervous function. The parasympathetic nervous system is reportedly less active in individuals who are sensitive to cold than in healthy people who are not [17]. It has been suggested that peripheral circulatory hypofunction is caused by excessive sympathetic nerve activity [17]. Evaluation of autonomic nervous system function is required in future. Univariate analysis showed that participants with taste disturbance and 2OSC were taking significantly more medications than the other participants. Recently, polypharmacy was identified as an issue in older individuals because it is associated with frailty [18] and falls [19]. Polypharmacy may also be an issue in perimenopausal women. Agents targeting the central nervous system were more frequently taken by participants with burning mouth and 2OSC than by those without these characteristics. However, it is difficult to identify the adverse effects of medications because these symptoms can also occur in people with mental health concerns. Univariate analysis also showed that participants with taste disturbance and burning mouth had a significantly better TCI than those who did not. There are two possible explanations for this finding. One is that these participants’ tongue papillae were too atrophied to allow development of a tongue coating. Atrophy of tongue papillae may cause taste disturbance or a burning sensation. The other possible explanation is tongue cleaning. Participants who experience taste distortion or abnormal sensations in their tongues may tend to clean them with tongue brushes more frequently. In this study, we did not investigate the state of tongue papillae or frequency of tongue cleaning. This study had some limitations. The symptoms investigated were only assessed on the basis of participants’ subjective experiences; no diagnoses were made. We did not determine taste thresholds or do tests to exclude tongue cancer and other tongue disorders. Additionally, we did not use an accelerometer to evaluate autonomic nervous system function objectively [20]. Evaluation of autonomic nervous system function and measurement of the blood flow in the oral mucosa is required to further investigate these possibilities. Furthermore, we did not check serum estrogen concentrations. Some participants reported xerostomia but had normal saliva volumes. That is, xerostomia and hyposalivation did not invariably coexist. Although QOL is impacted by subjective sensations, not objective diagnoses, investigation of objective factors is needed to clarify the relationship between these symptoms and menopause. In conclusion, we found associations between the number of menopausal symptoms and xerostomia, taste disturbance, burning mouth and 2OSC in our cohort of perimenopausal women. Effective management of all of these symptoms may decrease the incidence and severity of oral discomfort, improving the QOL of perimenopausal women. Additional file 1. Supplementary table 1. Additional file 2. Supplementary table 2.
  17 in total

Review 1.  Xerostomia: etiology, recognition and treatment.

Authors:  James Guggenheimer; Paul A Moore
Journal:  J Am Dent Assoc       Date:  2003-01       Impact factor: 3.634

2.  Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices.

Authors:  H S KUPPERMAN; M H BLATT; H WIESBADER; W FILLER
Journal:  J Clin Endocrinol Metab       Date:  1953-06       Impact factor: 5.958

3.  Sialochemical and gustatory analysis in patients with oral sensory complaints.

Authors:  Rafael M Nagler; Oded Hershkovich
Journal:  J Pain       Date:  2004-02       Impact factor: 5.820

4.  New method for evaluation of tongue-coating status.

Authors:  T Shimizu; T Ueda; K Sakurai
Journal:  J Oral Rehabil       Date:  2007-06       Impact factor: 3.837

5.  Oral symptoms at menopause--the role of hormone replacement therapy.

Authors:  L Tarkkila; M Linna; A Tiitinen; C Lindqvist; J H Meurman
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2001-09

6.  Oral complaints and stimulated salivary flow rate in 1188 adults.

Authors:  Makoto Toida; Yuki Nanya; Tomoko Takeda-Kawaguchi; Seiji Baba; Kazuki Iida; Keizo Kato; Daijiro Hatakeyama; Hiroki Makita; Tomomi Yamashita; Toshiyuki Shibata
Journal:  J Oral Pathol Med       Date:  2010-02-28       Impact factor: 4.253

7.  A natural S-equol supplement alleviates hot flushes and other menopausal symptoms in equol nonproducing postmenopausal Japanese women.

Authors:  Takeshi Aso; Shigeto Uchiyama; Yasuhiro Matsumura; Makoto Taguchi; Masahiro Nozaki; Kiyoshi Takamatsu; Bunpei Ishizuka; Toshiro Kubota; Hideki Mizunuma; Hiroaki Ohta
Journal:  J Womens Health (Larchmt)       Date:  2011-10-12       Impact factor: 2.681

8.  Polypharmacy Is Associated With Higher Frailty Risk in Older People: An 8-Year Longitudinal Cohort Study.

Authors:  Nicola Veronese; Brendon Stubbs; Marianna Noale; Marco Solmi; Alberto Pilotto; Alberto Vaona; Jacopo Demurtas; Christoph Mueller; Jonathan Huntley; Gaetano Crepaldi; Stefania Maggi
Journal:  J Am Med Dir Assoc       Date:  2017-04-07       Impact factor: 4.669

9.  Association between polypharmacy and falls in older adults: a longitudinal study from England.

Authors:  Nafeesa N Dhalwani; Radia Fahami; Harini Sathanapally; Sam Seidu; Melanie J Davies; Kamlesh Khunti
Journal:  BMJ Open       Date:  2017-10-16       Impact factor: 2.692

10.  The Relationship between Menopausal Symptoms and Heart Rate Variability in Middle Aged Women.

Authors:  Jin Oh Lee; Sung Goo Kang; Se Hong Kim; Seo Jin Park; Sang Wook Song
Journal:  Korean J Fam Med       Date:  2011-07-28
View more
  1 in total

Review 1.  Changes in the Oral Cavity in Menopausal Women-A Narrative Review.

Authors:  Aleksandra Ciesielska; Aida Kusiak; Agata Ossowska; Magdalena Emilia Grzybowska
Journal:  Int J Environ Res Public Health       Date:  2021-12-27       Impact factor: 3.390

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.